<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200611047727N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-06-23</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of using the inspiratory muscle training device (IMT) on the thickness and excursion  of the diaphragm of COPD patients</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of using the inspiratory muscle training device (IMT) on the thickness and excursion  of the diaphragm of COPD patients undergoing lung rehabilitation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>221</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84144</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method: Simple, Randomization unit: Individual, Randomization tool: Random number table. Simple randomization method is used for randomization with the help of a random number table. For this purpose, two groups are named A and B. We choose one of the rows of the random number table at will and the numbers of each row will be between 0 and 9. We assign the numbers 0-4 to treatment A and the numbers 5-9 to treatment B, Blinding description: Ultrasound scans of patients are performed by an experienced radiologist blind to the patient's other tests (on two occasions before the start of rehabilitation and at the end of the rehabilitation period).</study_design>
      <phase>3</phase>
      <hc_freetext>Chronic obstructive pulmonary disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients are hospitalized for 2 weeks and during this time they perform daily pulmonary rehabilitation exercises including diaphragmatic breathing, pursed lip breathing and respiratory stretching exercises along with aerobic exercise. In addition, patients use the IMT device. After 2 weeks, patients are discharged after receiving a home pulmonary rehabilitation program and exercise training. Patients continue their rehabilitation process at home as remote rehabilitation with the IMT device (for 6 weeks). To use the IMT device, the patient performs 30 repetitions in the morning and 30 repetitions in the afternoon every day, and the resistance of the device is gradually increased. At the end of 6 weeks, the patient returns to the hospital (rehabilitation department) and the desired evaluations will be performed. Intervention 2: Control group: Patients are hospitalized for 2 weeks and during this period, they perform daily breathing exercises including diaphragmatic breathing, pursed lip breathing, and respiratory stretching exercises for 20 minutes on the bed and under the direct supervision of a physiotherapist, along with aerobic exercise including at least 15 minutes of walking on a treadmill at a maximum speed equivalent to 80% of the six-minute walk test. After two weeks, patients are discharged after receiving a remote rehabilitation program and continue their rehabilitation program at home (under the supervision of the hospital rehabilitation team) for 6 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoumeh Zoghali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Masih Daneshvari Hospital, Daarabad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956944413</zip>
        <telephone>+98 21 2610 5050</telephone>
        <email>masoumezoghali@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Sadat Mirenayat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Masih Daneshvari Hospital, Daarabad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956944413</zip>
        <telephone>+98 21 2612 5050</telephone>
        <email>MirenayaT_M@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years
Diagnosis of COPD based on GOLD</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Hemoptysis
embolism
lung cancer
pneumothorax
acute cardiovascular problems
diaphragmatic paralysis
severe dyspnea preventing testing
patient's unwillingness to continue participating in the research project</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J44</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other chronic obstructive pulmonary disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients are hospitalized for 2 weeks and during this time they perform daily pulmonary rehabilitation exercises including diaphragmatic breathing, pursed lip breathing and respiratory stretching exercises along with aerobic exercise. In addition, patients use the IMT device. After 2 weeks, patients are discharged after receiving a home pulmonary rehabilitation program and exercise training. Patients continue their rehabilitation process at home as remote rehabilitation with the IMT device (for 6 weeks). To use the IMT device, the patient performs 30 repetitions in the morning and 30 repetitions in the afternoon every day, and the resistance of the device is gradually increased. At the end of 6 weeks, the patient returns to the hospital (rehabilitation department) and the desired evaluations will be performed.</i_keyword>
      <i_keyword>Control group: Patients are hospitalized for 2 weeks and during this period, they perform daily breathing exercises including diaphragmatic breathing, pursed lip breathing, and respiratory stretching exercises for 20 minutes on the bed and under the direct supervision of a physiotherapist, along with aerobic exercise including at least 15 minutes of walking on a treadmill at a maximum speed equivalent to 80% of the six-minute walk test. After two weeks, patients are discharged after receiving a remote rehabilitation program and continue their rehabilitation program at home (under the supervision of the hospital rehabilitation team) for 6 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Diaphragmatic excursion. Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Ultrasound.</prim_outcome>
      <prim_outcome>Diaphragmatic thickness. Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Ultrasound.</prim_outcome>
      <prim_outcome>Forced vital capacity (FVC). Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Spirometry.</prim_outcome>
      <prim_outcome>Forced expiratory volume in one second (FEV1). Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Spirometry.</prim_outcome>
      <prim_outcome>Predicted FVC. Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Spirometry.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Six minute walk test distance. Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Six minute walk test.</sec_outcome>
      <sec_outcome>Dyspnea. Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Based on modified medical research council dyspnea scale questionnaire.</sec_outcome>
      <sec_outcome>Quality of life. Timepoint: At the beginning of hospitalization, after two weeks (at discharge), and also after 6 weeks of tele-rehabilitation. Method of measurement: Based on the St. George questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-05-27</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Abbas Arabi St., Yemen St., Shahid Chamran Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
